Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 versus AMINOSYN II 7 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 7 versus AMINOSYN II 7 W ELECTROLYTES.
AMINOSYN 7% vs AMINOSYN II 7% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 7% provides a mixture of essential and nonessential amino acids, serving as substrates for protein synthesis, thereby supporting nitrogen balance and tissue repair. It acts as a source of caloric nitrogen in parenteral nutrition.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Intravenous: 500 mL to 2 L of 7% solution (35-140 g amino acids) per day by central or peripheral infusion, adjusted based on metabolic needs and nitrogen balance, usually infused at a rate not exceeding 0.1 g/kg/hour.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
None Documented
None Documented
Not applicable as a single entity; amino acids are utilized rapidly for protein synthesis and energy. Plasma amino acid levels decline with a terminal half-life of approximately 10-20 minutes post-infusion, reflecting rapid tissue uptake.
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Primarily renal elimination of infused amino acids as metabolic byproducts (urea, ammonia) and a small fraction of unchanged amino acids. Renal excretion accounts for >90% of elimination; negligible biliary/fecal.
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution